Acacia Research Reports Third Quarter 2022 Financial Results
Adds two U.S. Food and Drug Administration (“FDA”) approved new chemical entities with strong patent protectionBARHEMSYS® (amisulpride for injection) and BYFAVO® (remimazolam for injection) join Eagle...
Acacia Pharma Group PLC THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AND REGULATED INFORMATION NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO...
Acacia Pharma Group PLC THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AND REGULATED INFORMATION NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO...
Acacia Pharma Group PLC THIS ANNOUNCEMENT CONTAINS REGULATED INFORMATION NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION...
THIS ANNOUNCEMENT CONTAINS REGULATED INFORMATION. Publication in application of Article 15 of the Law of 2 May 2007 (the Transparency Law) Cambridge, UK and Indianapolis, US – 31 March 2022, 18:00...
THIS ANNOUNCEMENT CONTAINS REGULATED INFORMATION Not for release, publication or distribution, in whole or in part, directly or indirectly in, into or from any jurisdiction where to do so would...
Eagle Pharmaceuticals has signed an agreement for the acquisition of UK-based hospital pharmaceutical company Acacia Pharma, by way of a scheme of arrangement, for nearly $104m (€94.7m), or $1 (€0.9) per share on a fully diluted basis.
This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014. Cambridge, UK and Indianapolis, US – 23 March 2022: Acacia Pharma Group...
As previously announced1, Acacia Pharma Group plc issued ordinary shares to its Employee Benefit Trust within the authorised capital. The gross amount of this capital increase amounted to GBP 22,909.44 via an issue of 1,145,472 new shares at an issue price of GBP 0.02 per share. The shares were issued to satisfy the vesting of share awards granted under the Company’s Performance Share Plan.